Visen Pharmaceuticals
As of the edition of 20 October 2026, Visen Pharmaceuticals runs 3 drugs, 3 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 3 |
| Total | 3 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Palopegteriparatide | Ends 2037 (patent) | 3 |
| Navepegritide | Ends 2037 (patent) | 1 |
| Lonapegsomatropin | Ends 2033 (computed from the first US licence) | 1 |
A route B row is one company at one target.
Where its trials are
- Hormones: 3 trials led
- Bones, joints and muscles: 2 trials led
- Inherited and neonatal: 1 trials led